Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc > the perfect situation

<< Previous

Bullboard Posts

Next >>

Post by bingostaron Dec 22, 2022 6:08pm

473 Views

Post# 35188229

the perfect situation

With a market cap trading under the cash in the cie and 3 products in clinic phase announcing news in the coming weeks you cannot dream of a better scenario . On top of it the CEO Pierre Lemieux who sold Biolactis to Nestl for a massive gain could deal an historic deal with a big pharma for 1 or all products in the pipeline.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant